PATENT Case No. MS0007YF

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

N. Smith et al.

DEC 2 0 2005

Serial No.

10/506,479

Filed: September 1, 2004

For: DI-ARYL SUBSTITUTED TERTAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Art Unit:	1625	
Examiner:		 

## INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR 1.97**

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

Date\_

3

## INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

OIPE	TPE RELATED APP		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE	
DEC 2 0 2005			
To Stance Market			
A THAN DE MANAGEMENT			

If th	is is inconvenient, additional copies will be submitted upon request.	,	
6	6. In accordance with 37 C.F.R. 1.97, (check one)		
	the attached information is filed within three months of the filing dat	e of the captioned case.	
$\checkmark$	the attached information is filed more than three months after the fi Office Action on the merits.	ling date but prior to the ma	ailing of a first
	the attached information is filed before the mailing of a first Office a examination under §1.114.	ction after the filing of a re-	quest for continued
	the attached information is being filed more than three months after Office Action on the merits, but before the mailing date of a Final Action of the respective of the mailing date of a Final Action. The enclosed auth Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).	ction, Notice of Allowance,	or an action that
	each item of information contained in this Information Disclosure St from a foreign patent office in a counterpart foreign application not Statement.		= -
	each item of information contained in the information disclosure state a foreign patent office in a counterpart application and this communication designated in §1.56(c) more than thirty days prior to the filing of the	nication was not received b	y any individual
	no item of information contained in this Information Disclosure State foreign patent office in a counterpart foreign application, and, to the after making reasonable inquiry, was known to any individual design months prior to the filing of this Statement.	knowledge of the person s	signing the certification
		Respectfully submitted,	
			•

By: David A. Rubin

Attorney For Applicant(s)

Reg. No. 40,314

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-<u>2675</u>

Date: December 15, 2005

Substitute for form 1449A/PTO	COMPLETE IF KNOWN		
INFORMATION DISCLOSURE	Application Number	10/506,479	
STATEMENT BY APPLICANT	Filing Date	September 1, 2004	
۱ کے ۱	First Named Inventor	N. Smith et al.	
( DEC 2 0 2005 %)	Group Art Unit	1625	
(use as many speets as necessary)	Examiner Name		
et of 2	Attorney Docket Number	MS0007YP	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY
l					

FOREIGN PATENT DOCUMENTS						
		Foreign Patent Document				Date of Publication of
	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
			<del>-</del>			
			<del></del>			
			•			•
Examin Signatu	er re				Date Considered	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form \* IDS Form\* (IDS Folder), Merck & Co., Inc., -7/12/2005)

	Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE	
COMPLETE IF KNOWN		
Application Number	10/506,479	
Filing Date	September 1, 2004	
First Named Inventor	N. Smith et al.	
Group Art Unit	1625	
Examiner Name		
Attorney Docket Number	MS0007YP	
	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.		
	A	CAPLUS Accession No.: 1986:511139, Kitaeva, et al. Radioprotective and antitumor activity of some tetrazole derivatives" Khimiko-Farmatsecticheskii Zhurnal (1986), Vol. 20, No. 5, pp. 559-63		
	!			

Examiner Signature	Date Considered	